Mrkt BUZZ DanCann

Mrkt BUZZ DanCann Pharma: Financing secured

10 aug 2021

Read the commentary here:

Mrkt BUZZ Dancann Pharma 10 Aug 2021 EN


Financing secured

On March 31 the company had cash and cash equivalents of DKK 12.7m, down from 21.3m three months before. The company has moderate quarterly expenses, but it has a large cash outflow due to investments into its biotech farm. More investments are needed before commercial cannabis production can commence.

When the company was listed last year, the plan was to fund further expansions through warrants. A total of 2 668 000 warrants (To1) were issued at IPO. With a strike price of DKK 6.0, the company could receive DKK 16m if they are fully subscribed. However, as the subscription period is from 1 to 17 September 2021 and the share price has been just at or below DKK 4.0 during the last three months, the probability that To1 expires out of the money is relatively large. Therefore, the directed share issue and the simultaneously acquired loan on 16 July that together were valued at DKK 16.326m is strategically important. If the company had waited until the warrants expired, there is a large risk that investors would have sold off the share in expectation of a share issue.

We think that the management of DanCann has shown good judgement in its pre-emptive action. The company now has the funds necessary to accomplish the goals it set out in the IPO prospectus.

On the other hand, there is also a cost involved. The main part of the money injected comes in the shape of a loan from Modelio Equity and Gerhard Dal with a monthly interest rate of 1,5%. This corresponds to an almost 20% yearly accrual rate. Management believes that the share price is too low for a common share issue and that this non-dilutive form of financing is superior. A share issue at a lower share price would be more expensive in the form of dilution. Eventually, it is likely that the company will have to raise money through a share issue to repay this debt, but it should be possible at a higher share price if the company succeeds with its business plan.

The shares issued worth DKK 6.375m were subscribed largely part by management and long-term investors. At DKK 3.745, no discount was given. We find it positive that management believes in the company and invests in it at market price. A warrant that can be subscribed at DKK 4.8685 was included in the direct share issue.

Carlsquare published the latest research update on DanCann Pharma on June 3, 2021, with a fair value per share of DKK 7.0. Read the full report here.


Disclaimer

Carlsquare AB, www.carlsquare.se, hereinafter referred to as Carlsquare, conducts business with regard to Corporate Finance and Equity Research in which areas it, among other things, publishes information about companies including analyzes. The information has been compiled from sources that Carlsquare considers to be reliable. However, Carlsquare cannot guarantee the accuracy of the information. Nothing written in the analysis should be regarded as a recommendation or invitation to invest in any financial instrument, option or the like. Opinions and conclusions expressed in the analysis are intended only for the recipient.

The content may not be copied, reproduced or distributed to another person without the written approval of Carlsquare. Carlsquare shall not be held responsible for any direct or indirect damage caused by decisions made on the basis of information contained in this analysis. Investments in financial instruments provide opportunities for value increases and profits. All such investments are also subject to risks. Risks vary between different types of financial instruments and combinations of these. Historical returns should not be considered as an indication of future returns.

The analysis is not directed to U.S. persons (as defined in Regulation S of the United States Securities Act and interpreted in the United States Investment Company Act 1940) nor may it be disseminated to such persons. The analysis is also not directed to such natural and legal persons where the distribution of the analysis to such persons would result in or entail a risk of a violation of Swedish or foreign law or constitution.

The analysis is a so-called Commissioned Research Report where the analysed Company has signed an agreement with Carlsquare for analysis coverage. The analyses are published on an ongoing basis during the contract period and for a usual fixed remuneration.

Carlsquare may or may not have a financial interest in the subject of this analysis. Carlsquare values the assurance of objectivity and independence and has established procedures for managing conflicts of interest for this purpose.

The analysts Jonatan Andersson, Markus Augustsson and Richard Ramanius do not own and are not allowed to own shares in the company analysed.

 

Team

Bild av Jessica Algner
Jessica Algner

Assistant

Telefon: +49 30 809 33 47-12

LinkedIn

@

Bild av Polina Amini
Polina Amini

Senior Associate

Telefon: +49 40 300 836-14

LinkedIn

@

Bild av Jonatan Andersson
Jonatan Andersson

Equity Analyst

Telefon: +46 70 508 00 51

LinkedIn

@

Bild av Markus Augustsson
Markus Augustsson

Head of Equity Research

Telefon: +46 76 235 03 20

LinkedIn

@

Bild av Agata Barsallo
Agata Barsallo

Office Management & Accounting

Telefon: +44 20 8017 6020

@

Bild av Caroline Berglund
Caroline Berglund

Head of Equity Sales

Telefon: +46 73 382 10 82

LinkedIn

@

Bild av Anders Bo
Anders Bo

Managing Partner

Telefon: +45 4199 8252

LinkedIn

@

Bild av Ulf Boberg
Ulf Boberg

Senior Advisor Life Sciences

Telefon: +46 73 312 44 90

LinkedIn

@

Bild av Manfred Drax
Manfred Drax

Partner

Telefon: +49 89 255 49 53-15

LinkedIn

@

Bild av Anders Elgemyr
Anders Elgemyr

Managing Partner

Telefon: +46 70 496 18 15

LinkedIn

@

Bild av Niklas Elmhammer
Niklas Elmhammer

Senior Equity Analyst

Telefon: +46 898 39 59

LinkedIn

@

Bild av Sebastian Fischer
Sebastian Fischer

Director

Telefon: +49 89 255 49 53-12

LinkedIn

@

Bild av Daniel Garlipp
Daniel Garlipp

Managing Partner

Telefon: +49 40 300 836-19

LinkedIn

@

Bild av Philip Goldhahn
Philip Goldhahn

Vice President

Telefon: +49 40 300 836-21

LinkedIn

@

Bild av Thorsten Grandt
Thorsten Grandt

Vice President

Telefon: +49 30 809 33 47-20

LinkedIn

@

Bild av Johan Heigard
Johan Heigard

Vice President

Telefon: +46 70 246 99 88

LinkedIn

@

Bild av Caroline Heintz
Caroline Heintz

Senior Associate

Telefon: +46 707 40 68 58

@

Bild av Maurice Hinrichs
Maurice Hinrichs

Associate

Telefon: +49 40 300 836-20

LinkedIn

@

Bild av Arnold Holle
Arnold Holle

Managing Partner

Telefon: +44 20 80176020

LinkedIn

@

Bild av Lars Johansen
Lars Johansen

IT&Telecom Expert

@

Bild av Elaine Kelly
Elaine Kelly

Head of Marketing

Telefon: +49 40 300 836 18

LinkedIn

@

Bild av Anna-Lena Kickbusch
Anna-Lena Kickbusch

Office Management & Accounting

Telefon: +49 40 300 836 10

LinkedIn

@

Bild av Morten Kjærulff
Morten Kjærulff

Partner

Telefon: +45 2634 9031

LinkedIn

@

Bild av Mischa Krause
Mischa Krause

Director

Telefon: +49 40 300 836-24

LinkedIn

@

Bild av Steffen Leckert
Steffen Leckert

Managing Partner

Telefon: +49 89 255 49 53 26

LinkedIn

@

Bild av Malve Liebig
Malve Liebig

Senior Associate

Telefon: +49 89 255 49 53-18

LinkedIn

@

Bild av Erik Lundberg
Erik Lundberg

Partner

Telefon: +46 73 850 35 59

LinkedIn

@

Bild av Eva Macha
Eva Macha

Office Management & PA to Michael Moritz

Telefon: +49 30 809 33 47-10

LinkedIn

@

Bild av Mandy May
Mandy May

Head of Operations

Telefon: +49 30 809 33 47 16

LinkedIn

@

Bild av Mirja Meyer
Mirja Meyer

Office Management & Accounting

Telefon: +49 40 300 836 10

@

Bild av Mark Miller
Mark Miller

Managing Partner

Telefon: +49 40 300 836-11

LinkedInXING

@

Bild av Michael Moritz
Michael Moritz

Managing Partner

Telefon: +49 30 809 33 47-13

LinkedIn

@

Bild av Bertil Nilsson
Bertil Nilsson

Senior Equity Analyst

Telefon: +46 70 434 90 03

LinkedIn

@

Bild av Flemming C. Pedersen
Flemming C. Pedersen

Managing Partner

Telefon: +45 4199 8251

LinkedIn

@

Bild av Anika Schaefer
Anika Schaefer

Office Management & HR

Telefon: +49 89 255 495 310

@

Bild av Alexander Schleppegrel
Alexander Schleppegrel

Associate

Telefon: +45 2621 0543

LinkedIn

@

Bild av Nico Schmidt-Weidemann
Nico Schmidt-Weidemann

Managing Partner

Telefon: +49 89 255 49 53-17

@

Bild av Caspar Graf Stauffenberg
Caspar Graf Stauffenberg

Managing Partner

Telefon: +49 89 255 49 53-11

LinkedIn

@

Bild av Jon Tingling
Jon Tingling

Vice President

Telefon: +44 77 1347-8286

LinkedIn

@

Bild av Sybille de Vegvar
Sybille de Vegvar

Business Development & Marketing

Telefon: +44 20 8017 6017

@

Bild av Oskar Wollert
Oskar Wollert

Vice President

Telefon: +46 761 71 11 60

@

Bild av Jan-Frederik Zapp
Jan-Frederik Zapp

Associate

Telefon: +49 30 8093347-31

LinkedIn

@

Bild av Nils Zettelmeyer
Nils Zettelmeyer

Director

Telefon: +49 30 809 33 47-25

LinkedIn

@

Bild av Andreas Zetzsche
Andreas Zetzsche

Partner

Telefon: +49 30 809 3347 33

@

Bild av Marta Zientarski
Marta Zientarski

Vice President

Telefon: +46 73 840 55 66

@